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As neuronal pathologies cause only minor morphological alterations, molecular imaging
techniques are a prerequisite for the study of diseases of the brain. The development
of molecular probes that specifically bind biochemical markers and the advances of
instrumentation have revolutionized the possibilities to gain insight into the human
brain organization and beyond this—visualize structure-function and brain-behavior
relationships. The review describes the development and current applications of
functional brain imaging techniques with a focus on applications in psychiatry. A historical
overview of the development of functional imaging is followed by the portrayal of
the principles and applications of positron emission tomography (PET) and functional
magnetic resonance imaging (fMRI), two key molecular imaging techniques that have
revolutionized the ability to image molecular processes in the brain. We conclude that
the juxtaposition of PET and fMRI in hybrid PET/MRI scanners enhances the significance
of both modalities for research in neurology and psychiatry and might pave the way for
a new area of personalized medicine.
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Principles of Diagnostic Imaging
Traditionally, diagnostic imaging was restricted to the visualization of aberrations in morphological
structures. However, neurological pathologies generally do not cause significant correlates
to macroscopically or microscopically visible changes in cell morphology. Since the contrast
obtained for the differentiation of pathophysiological abnormality defines the performance of an
imaging modality, highly sensitive methods for imaging alterations in brain functioning had to be
developed. In general, any kind of radiation that penetrates the human body can be used as signal
source for diagnostic imaging. Hence, the diversity of imaging modalities reflects the variety of
the capabilities of the different kinds of radiation used in clinical practice. The aim of this short
review is to introduce the principles of the most common and most promising molecular imaging
techniques for the investigation of alterations in brain functioning: positron emission tomography
(PET) and functional magnetic resonance imaging (fMRI) and to deduce their limitations and
prospects.
The contemporary imaging methods: computer tomography (CT), magnetic resonance
imaging (MRI), PET, and ultrasound (US) can be traced back to the German physicist
Wilhelm Conrad Röntgen. In 1895 Röntgen recognized that X-rays penetrate solid mater.
He further discovered that the attenuation of X-rays depends on the characteristics of the
object penetrated. When he subsequently deduced the technique of X-ray imaging a great
invention took place: the visualization of structures inside the body without using surgery!
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Since then the imaging with X-rays has been shown to provide
images of excellent anatomic resolution. The development of CT,
the corresponding tomographic modality, has further enhanced
X-ray imaging and up to the present billions of scans have
been carried out. The specific strength of CT imaging is its
high anatomic resolution. The imaging is straightforward as
long as bony materials or calcified tissue is investigated. In
soft tissues the differences of X-ray attenuation are marginal
and contrast agents are used to provide the known high-quality
CT images in the major areas of the body i.e., the vascular
system, the lungs and the kidneys. Inclusion of elements of
high atomic number is pivotal for the efficacy of CT contrast
agents as the X-ray absorbency is almost directly proportional
to the third power of an elements atomic number. However,
unfortunately, most elements of high atomic number are not
biocompatible and iodine containing contrast agents dominate
the choice of contrast agents in clinical use. High doses of up
to 42 g of the contrast agent are required to induce sufficient
contrast (Mortelé et al., 2005). Hence, for brain imaging in
particular the highly sensitive methods PET and MRI are more
promising.
Principles of Molecular Imaging
When it comes to the tasks faced in brain imaging, the assessment
of cellular functions and the visualization of metabolic processes
is required. The visualization of changes of essential cellular
structures gives testimony about the health status of a cell long
before macroscopically or microscopically visible changes in
cell morphology occur. These sensitive phenomena are only
accessible to investigations with tracers/imaging agents and in
the most delicate cases extremely small numbers of receptors are
available to trigger the specific accumulation of the imaging agent
(Catana et al., 2012).
Generally, there are two types of imaging agents to be
differentiated (a) passive agents that modulate an external
signal i.e., in CT and US; and (b) probes that either produce
a signal autonomously i.e., radiotracers and bioluminescent
dyes, or transformations of an external signal, such as with
MRI contrast agents or fluorescent probes. As passive contrast
agents only enhance the body’s signal, relatively high doses are
required to delineate their endogenous contrast. While very high
concentrations of CT contrast agents are required, the signal
of radiolabeled tracers can be measured at an exceptionally
high sensitivity. As the radioactive signal is exclusively emitted
by the endogenous tracer it can be definitively traced back to
the imaging agent. The short lived positron emitters 11C and
18F are ideal for molecular imaging purposes. The positrons
emitted by these radioisotopes produce gamma rays upon
collision with electrons. These gamma rays efficiently penetrate
the body and are detected in the PET scanner. The radioisotope
is linked to a tracer molecule that triggers specificity by i.e.,
binding neuroreceptors or tracking the hemodynamics of the
brain. Due to their pivotal function in neurotransmission
and neuromodulation, the assessment of the spatial and
temporal activity of neuroreceptors virtually depicts the brain
functions and physiologic activities. Hence, PET tracers are
the prototype of imaging agents for functional brain imaging,
and PET studies have been proven of vital importance for
the understanding and therapy of neurologic and psychiatric
disorders.
Applications for PET Tracers
Selective radioligands are often derived from psychoactive drugs
and gain their specificity by mimicking neurotransmitters. The
visualization of their specific binding to a target such as a
receptor, a transporter or an enzyme allows revealing various
pathologic conditions. In the following, PET tracers will be
reviewed that target receptors, proteins or neurotransmitter, or
glucose consumption.
Typical examples of radiotracers for PET are the ligands
for the quantitative imaging of specific neuroreceptor subtypes
such as [11C]raclopride and [18F]fallypride for dopamine D2/D3
receptors for differential diagnosis of movement disorders and
for assessment of receptor occupancy by neuroleptics drugs in
schizophrenia (Siessmeier et al., 2005). Tracers binding arterial
nicotinic acetylcholine receptors and acetylcholinesterase such
as [18F]-2-fluoro-A85380 have been developed as markers of
cognitive and memory impairment as well as Parkinson’s disease
or multiple system atrophy (Bucerius et al., 2012). [11C]DASB,
[11C]McN 5652 and [18F]FMe-McN5652 have been shown
to bind serotonin (5-hydroxytryptamine, 5-HT) receptors and
the 5-HT transporter. These transporters are dysregulated in
affective disorders and shall be valuable structures for the
assessment of activity of antidepressants. In the midbrain and
amygdala of patients with major depressive disorder lower
5-HT transporter binding can be assessed with tracers such
as [11C]McN5652 (Parsey et al., 2006). Furthermore, this
group of tracers is capable to determine abnormalities in both
serotonin transporter and dopamine transporter binding as a
result of the abnormalities in the neurotransmitter systems
of the brains of autistic individuals (Hesse et al., 2012). Due
to the salient role of opioid systems in neuropathic pain
(Maarrawi et al., 2013), PET imaging of opioid receptors
facilitates the understanding of the molecular and cellular
mechanisms of pain generation and assists the use and
advancement of pain medication, spinal cord stimulation and
spinal infusion pumps. The opioid receptor binding tracer
[11C]diprenorphine reveals reduced opioid receptor densities
in neuropathic pain patients. Another tracer that binds to
the GABA-receptors [11C]flumazenil has been used to study
increased cortical excitability in focal epilepsy (Szelies et al.,
2002).
The pervasive search for drug treatments targeting
Alzheimer’s disease has stimulated tracers to provide an
intimate link to the diagnostics of this potential blockbuster
market. Radiotracers binding the plaque forming proteins beta-
amyloid- and tau-protein represent a straightforward approach
for this disease. Subsequently, a series of different tracers ofthe
Pittsburgh compound, e.g., florbetaben and flutemetamol have
recently been approved for the detection of Alzheimer’s disease
related protein plaques and the accompanying potential of
staging this disease (Nordberg et al., 2010). Interestingly, a
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radiolabeled derivative of the dye thioflavin T was shown to
bind the amyloid protein deposits in the brains of patients
suffering from Alzheimer’s disease (Kreisl et al., 2013). Other
examples for the various PET tracers for neuroimaging are
6-[18F]fluoro-L-DOPA that allows the imaging of presynaptic
dopamine and can be used to determine dopamine turnover in
Parkinson patients (Sossi et al., 2002).
The study of tracers that map the regional differences of blood
flow represents a different approach to visualize pathological
changes and to gain function information of the brain. 15O-H2O
is the gold standard for this purpose (Grüner et al., 2012).
This is complemented by 2-[18F]fluoro-2-deoxy-D-glucose
(FDG), the working horse of modern molecular imaging (de
Leon et al., 2001). In addition, to provide perfusion data,
FDG allows conclusions about neuronal activity based on the
energy metabolism. FDG is taken up by glucose transporters
and trapped inside the cell as its 6-phosphate as a result of
phosphorylation by the enzyme hexokinase. As the progression
of Alzheimer’s disease is accompanied by decreased brain
metabolism, FDG-PET can be used to diagnose its early stages
and for the differentiation from other processes of dementia
(Mosconi et al., 2008). Due to the short half-lives of 11C (20
min) and 18F (108 min) very small amounts of the tracer are
required to obtain the appropriate signal intensity and the total
radiation exposure is comparable to the one obtained by whole
body CT scans. The short half lives in turn entail the on demand
synthesis of the radiotracers ideally with a cyclotron in close
proximity to the PET imaging facility. The effective doses are
continuously reduced by using tracers with short physical and
biological half-lives, by minimizing the activity injected and by
the ongoing enhancement of the sensitivity of PET scanners.
Prinicples of Magnetic Resonance Imaging
While PET imaging allows the assessment of neurotransmitter
concentrations in the brain, it is not suitable to reveal micro- and
macroscopic structural aberrations in the white and gray matter.
In addition, PET cannot be used to detect rapid changes in brain
activation. Moreover, despite the enormous achievement of
PET imaging there is always a concern about the radiation risks
involved in this modality. Magnetic resonance spectroscopy
(MRS) represents an alternative as endogenous compounds
involved in the biochemistry of the brain are detected. The
resonance frequency of protons depends on their chemical
structure and MRS measures the concentration of marker
molecules such as methionine or lipids (van der Graaf, 2010).
Again, the performance of the imaging modality is limited by the
contrast enhancing molecules: the concentrations of significant
compounds such as neurotransmitters in the brain are far below
the detection limit. In contrast, the bulk of the signal in magnetic
resonance imaging comes from free water and this is present in
abundance. The sizeable differences varying from 99 percent in
the CSF over about 80 percent in gray matter to 70 percent in
white matter are the basis for the excellent soft tissue contrast
observed in MRI images of the brain (Neeb et al., 2006). Due to
its high spatial resolution and the possibility to detect chances
in brain morphology without the application of tracers, MRI has
become the clinically preferred method of imaging soft tissues,
such as the brain.
While in principle, MRI can be conducted without the
application of contrast agents to the patient, for diagnostic
purposes, e.g., early detection of strokes, contrast agents have
to be applied. At first glance the sensitivity of MRI is similar to
that of CT and high concentrations of the contrast agent should
be required. But there is a fundamental difference between the
contrast agents used in CT and MRI. The currently used MRI
contrast agents (mostly gadolinium complexes that cause T1-
shortening) are working indirectly by affecting the relaxation of
water molecules in their coordination sphere. Due to the high
exchange rate of water in the sphere of gadolinium complexes
a large number of water molecules are relaxed within one scan
(typically 2–3 s). As a result, an apparent several thousand fold
amplification of the effect is observed. Consequently, a huge
variety of MRI contrast agents have been developed (van der
Graaf, 2010).
After evidence for a link between nephrogenic systemic
fibrosis (NFS) and gadolinium contrast agents had been
described (Cowper et al., 2000), the risk of NSF has become an
important issue in radiology. There is a broad consensus that the
residual risk caused by gadolinium contrast agents only exists for
patients with impaired kidney function. Even though NFS was
associated with only an infinitesimal insignificant number of the
patients diagnosed with gadolinium contrast agents, their link
to the risk of NSF has greatly affected the development of MRI
contrast agents and the approval of novel MRI contrast agents by
the FDA has collapsed since. This is an unbearable situation: due
to their elemental role in patient care, MRI contrast agents hold
invaluable benefit for today’s health care. A discussion of the
obligation to strike between the benefits of novel contrast agents
and the risk of their widespread application (please consider that
out of necessity the formerly approved contrast agents are still
used!) is beyond the scope of this article.
Functional Magnetic Resonance Imaging
Given the difficulties described for the development of specific
MRI contrast agents, fMRI was developed in due course. As
discussed above, the success of MRI is in great part due to
the fact that an endogenous contrast agent is detected at high
sensitivity. fMRI provides further characteristics that contribute
to this exceptional performance. In the preferred application
of the fMRI technique the iron in deoxyhemoglobin acts as
a paramagnetic contrast agent similarly as gadolinium in the
common MRI contrast agents. The blood of adults contains
about 750 g of hemoglobin, an amount hardly to be attained
with endogenous contrast agents. In deoxygenated hemoglobin
the iron is paramagnetic as it has four unpaired electrons.
Upon oxidation, hemoglobin loses its contrast enhancing
properties. Consequently, the deoxyhemoglobin/oxyhemoglobin
ratio defines the signal intensity. The so called blood oxygen
level dependent (BOLD)-effect can be traced back to neural
activity (rather than spiking of neurons), probably mainly due
to increased uptake of glutamate in astrocytes (Logothetis et al.,
2001; Raichle, 2001).
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Several elementary features contribute to the unmatched
performance of fMRI for neurological applications: (a) its
clinical convenience—fMRI is performed with the standard MRI
scanners and does not require the injection of contrast agents,
but is achieved due to the measurement of an endogenous
contrast agent that is present at high concentration in the brain;
(b) the fact that the contrast agent is functional and responsible
to stimuli; (c) the fact that fMRI it is not associated with the
use of radioactive probes provides a high ease of repeatability
and therefore makes longitudinal studies of subjects possible;
and (d) the possibility to study not only alterations in brain
morphology that affect activation of a certain region, but also its
connectivity to other brain regions.
Applications for (f)MRI
Nowadays, MRI scans of the brain are standard in clinical care
in neurologic and psychiatric hospitals. Neurological, as well
as vascular diseases of the brain can be easily detected and
help guiding diagnostics and appropriate therapies. In addition,
fMRIs can be acquired prior to brain surgeries to allow the
surgeon an individualized anatomical mapping of visual and
motoric functions of the patient.
Moreover, fMRI has a prominent role in neurologic and
psychiatric brain imaging research. For the sake of brevity, the
following illustration of MRI and fMRI for psychiatric research
will be exemplarily illustrated for schizophrenia. MRI studies
on schizophrenia show a volume loss of brain tissue, specially
an enlargement of the ventricles, replicating earlier CT studies,
making it one of the most robust findings in MRI research
(Shenton et al., 2001). The first fMRI studies on schizophrenia
revealed dorsolateral prefrontal cortex and temporal cortex as
neural substrate of deficient cognition (Kindermann et al., 1997).
More recently, the focus has shifted to (a) the investigation
of socio-emotional processing in schizophrenia, as well as (b)
to the investigation of resting state to detect task independent
alterations in the connectivity of brain networks (Zhou et al.,
2007) that both give according evidence for prefrontal and
temporal alterations. Consequently, an additional achievement of
fMRI becomes obvious: fMRI does not only allow the detection
of altered brain activation, but also of altered brain connectivity,
indicating disturbed communication of brain areas. And indeed
schizophrenia that has long been described as a disorder of
disconnectivity, could be empirically linked to altered functional
(Meyer-Lindenberg et al., 2001), as well as structural (Burns
et al., 2003) prefrontal-temporal communication by means of
fMRI, and diffusion tensor imaging (DTI) that gives evidence
for myelin loss of white matter tracks. Another modality
of high interest in MRI scanners is MRS. By allowing the
investigation of glutamate in the prefrontal cortex of patients
with schizophrenia, MRS helps to solve another puzzle of the
cognitive deficits in schizophrenia, (Poels et al., 2014). Moreover,
attempts to investigate molecular processes in the brain by
means of fMRI are the imaging genetics studies that combine
genetic information for e.g., a certain SNiP that is known to
influence the availability of dopamine in the frontal cortex with
FIGURE 1 | Basic aspects of PET and fMRI. Left: chemical structures of common PET tracers used in neurological imaging and illustration of the induction of
relaxation by hemoglobin, Middle: General characteristics of PET versus fMRI, Right: Typical PET and fMRI images (both single subjects).
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brain activation (Mier et al., 2010). However, using MRS the
concentration of only few neurotransmitters can be estimated,
and imaging genetics studies might neglect epigenetic effects,
while PET has a wide range of possible molecular targets in
the brain that can be directly assessed. Notwithstanding the
additional advantages and necessities of MRS and imaging
genetics studies, a combination of (f)MRI and PET would allow a
direct comprehensive assessment of the functioning of individual
brain regions, as well as the interplay on the level of the
whole brain (see Figure 1 for a schematic comparison of PET
and (f)MRI).
Hybrid PET/fMRI
Generally, in PET the advances are driven by the development of
selective radioligands (i.e., tracers targeting Alzheimer’s disease)
and in fMRI the development of the instrumentation (i.e., the
implementation of high-field MRI into clinical applications),
as well as the analysis methods (i.e., advances methods for
connectivity analyses, such as dynamic causal modelling).
However, improvements of the specificity of molecular
imaging probes invariably go along with the loss of effectual
resolution as the orientation guide—the accumulation in
the non-target tissue is decreased. Hence, bimodal imaging
techniques that combine the outstanding molecular imaging
probabilities of PET with imaging techniques with a better spatial
resolution were developed. PET/CT is the prime example for
such a bimodal imaging technique as the anatomical information
gained at high resolution by CT synergistically matches the
functional information of PET imaging. Due to the lack of
tissue that provides significant attenuation of X-rays in the brain,
PET/CT images of the brain do not significantly benefit from
the CT-portion of the fused images. Since MRI has excellent
soft tissue contrast, MRI should be perfect to navigate the PET
information in the brain and high hopes are placed into the
clinical outcome of the PET/MRI scanners that currently emerge.
Hence, despite the exceptional technical challenges that had to
be mastered (Pichler et al., 2008), PET/MRI hybrid systems
have been developed. These PET/MRIs do not only allow to
acquire PET and MRI with the same machine, but to acquire
them simultaneously, because there is more to this combination
than the convergence of anatomical and molecular resolution.
While the determination of increases in neural activity and
metabolism by the BOLD effect at first glance resembles static
tracers that track the hemodynamics (i.e., CT and MRI blood
pool contrast agents), the BOLD effect gives insight into the
site of oxygen consumption and thus metabolic information.
Hemoglobin is not able to penetrate the blood brain barrier
but as it is triggered by the readily diffusible molecule oxygen,
it virtually reports on metabolism beyond the blood brain
barrier. Hence, this is the first time that it is possible to directly
and simultaneously investigate the activity of neurotransmitters
along with the activity and connectivity of a brain region. This
combined assessment will give rise to a next generation of
understanding brain function in healthy persons and patients
with mental illnesses, and thus gives rise to high promise on
the way to personalized therapies—the great white hope in
medicine.
Conclusions
Despite the complexity of the brain function, advances in
brain imaging techniques, in particular PET and MRI have
boosted the research in the structure and function of the
human brain. MRI has become the main modality for clinical
neuroimaging. While economical restrictions and unbalanced
safety concerns halt the development of novel tracers, fMRI
hemodynamic based strategies have strongly advanced the
progress of neuroimaging. The molecular imaging tracers
(predominantly radiotracers) for PET provide the basis not
only for a better understanding of molecular processes in the
brain, but also for the stratification procedures essential for
the safe development of individualized therapies. The directly
combined application of BOLD fMRI measuring brain function
with PET radiolabeled reporters that map the distribution
and function of receptors synergistic will form the basis of
a new area in today’s rapidly increasing insight into brain
function.
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